CD160: A Promising Drug Target and Biomarker for Chronic Pain

CD160: A Promising Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The pain associated with chronic diseases, such as diabetes, cancer, and rheumatoid arthritis, can significantly impact an individual's quality of life. While various treatments have been developed to manage chronic diseases pain, the availability of effective drug targets and biomarkers remains a significant challenge. The CD160 transmembrane isoform, also known as CD160, has emerged as a promising drug target and biomarker for the treatment of chronic pain.

CD160: Structure and Function

CD160 is a transmembrane protein that belongs to the Integrins family. It is expressed in various tissues, including the brain, skeletal muscles, heart, and intestine. The CD160 protein has a unique topology, with a transmembrane region that is involved in the protein's stability and functions as an adhesion molecule.

CD160 is well-known for its role in cell-cell adhesion, as it forms tight junctions between adjacent cells in various tissues. This process is critical for tissue repair, development, and regeneration. CD160 has also been shown to play a significant role in cancer progression, as it has been reported to be involved in the development and metastasis of various cancers.

In addition to its role in cell-cell adhesion, CD160 has also been shown to play a critical role in pain signaling. Chronic pain is often associated with increased levels of pro-inflammatory cytokines, which can lead to the activation and proliferation of pain- producing neurons. CD160 has been shown to regulate the production of pro-inflammatory cytokines, which may contribute to its potential as a pain-therapeutic drug.

CD160 as a Drug Target

The CD160 protein has been identified as a potential drug target for the treatment of chronic pain due to its unique structure and function. Several studies have shown that inhibiting CD160 can effectively reduce the production of pro-inflammatory cytokines and alleviate pain in various models of chronic pain, including experimental models of pain in animals and human patients.

One of the most promising strategies for targeting CD160 is the use of small molecules, such as inhibitors or modulators of CD160's intracellular signaling pathways. Several compounds have been shown to inhibit CD160's activity, including inhibitors of its protein kinase C (PKC) and FAK signaling pathways. These compounds have been shown to reduce pain in various models of chronic pain, including thermal and chemical pain.

Another approach to targeting CD160 is the use of monoclonal antibodies (mAbs), which are laboratory-produced molecules that can specifically bind to and inhibit CD160's function. MAbs have been shown to be effective in animal models of chronic pain, and several human clinical trials are currently underway to evaluate their safety and efficacy as pain-therapeutic agents.

CD160 as a Biomarker

CD160 has also been used as a biomarker for the assessment of chronic pain. The production of pro-inflammatory cytokines is well-documented in the context of chronic pain, and the activation of pain-producing neurons can be detected using various pain-related biomarkers . However, the accuracy of these biomarkers can be limited by their sensitivity and specificity, which may vary depending on the underlying cause of the pain.

CD160 has been shown to be involved in the production of pro-inflammatory cytokines, which can be used as a biomarker for the assessment of chronic pain. Several studies have shown that the levels of CD160 are significantly increased in the blood and tissue of individuals with chronic pain, compared to individuals without chronic pain. These studies suggest that CD160 may be a useful biomarker for the diagnosis and assessment of chronic pain.

Conclusion

In conclusion, CD160 is a promising drug target and biomarker for the treatment of chronic pain. Its unique structure and function, as well as its involvement in cell-cell adhesion and pain signaling, make it an attractive target for small molecules and monoclonal antibodies. Further research is needed to fully understand the potential of CD160 as a drug and biomarker for the treatment of chronic pain.

Protein Name: CD160 Molecule

Functions: Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells (PubMed:19109136, PubMed:11978774, PubMed:17307798). Receptor for both classical and non-classical MHC class I molecules (PubMed:9973372, PubMed:12486241). In the context of acute viral infection, recognizes HLA-C and triggers NK cell cytotoxic activity, likely playing a role in anti-viral innate immune response (PubMed:12486241). On CD8+ T cells, binds HLA-A2-B2M in complex with a viral peptide and provides a costimulatory signal to activated/memory T cells (PubMed:9973372). Upon persistent antigen stimulation, such as occurs during chronic viral infection, may progressively inhibit TCR signaling in memory CD8+ T cells, contributing to T cell exhaustion (PubMed:25255144). On endothelial cells, recognizes HLA-G and controls angiogenesis in immune privileged sites (PubMed:16809620). Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response (By similarity). On activated CD4+ T cells, interacts with TNFRSF14 and down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity)

The "CD160 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD160 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B